Market Introduction
Hematuria is a medical condition where presence of blood is found in the urine. Generally, urine does not contain RBC and hence this can result in serious issue that may also cause kidney stones, urinary tract infection and other inherited diseases.
Moreover, the high prevalence hematuria associated indications is expected to bolster the market growth during the forecast period. However, undiagnosed cases of associated indications limit the growth of the North America hematuria treatment market.
The pandemic has offered vital growth opportunities for the players operating in the kidney disease market. The possibilities were due to the rising numbers of patients affected by the coronavirus. For instance, according to the American Society of Nephrology report, in response to COVID-19, half coronavirus positive patients admitted to intensive care unit (ICU) experience kidney failure that requires some form of dialysis. The report stated that ~ 10% to 50% of patients in ICU showed kidney failure, nearly 17% of patients needed urgent dialysis, and 46% had shown some forms of acute kidney injury (AKI). Across the North American region, the US has registered the highest numbers of patients affected by the coronavirus. Thus, the rising numbers of patients are at higher risk of getting affected for acute kidney injury (AKI), including tubular injury with septic shock, micro-inflammation, increased blood clotting, and probable direct infection of the kidney. Therefore, it is expected to raise the demand for kidney disease management products leading to market growth in the coming future.
Market Overview and Dynamics
The North America hematuria treatment market is projected to reach US$ 419.7 million by 2028 from US$ 351.6 million in 2021; it is anticipated to grow at a CAGR of 2.6% from 2021 to 2028. Technological developments in medical devices and diagnostic procedures have led to various options for managing hematuria-associated indications, such as kidney stones, bladder stones, and urinary tract infections. The use of advanced treatment technologies is expected to enhance patient care. For instance, the implementation of robotics in surgeries for treating urolithiasis has gained popularity in recent years. Currently, Vinci Surgical System, by Intuitive Surgical Inc., is widely used in performing surgeries to treat urolithiasis. Similarly, the uptake of endourological interventions for kidney stones has increased significantly across various countries. It is also expected that advancements in associated indications are likely to support the North America hematuria treatment market during the forecast period.
Key Market Segments
In terms of type, the macroscopic hematuria segment accounted for the largest share of the North America hematuria treatment market in 2020. In terms of treatment, the drugs segment accounted for the largest share of the North America hematuria treatment market in 2020. In terms of indication, the urinary tract infection segment accounted for the largest share of the North America hematuria treatment market in 2020. In terms of end user, the hospitals segment accounted for the largest share of the North America hematuria treatment market in 2020.
Major Sources and Companies Listed
A few major primary and secondary sources referred to for preparing this report on the hematuria treatment market in North America are company websites, annual reports, financial reports, national government documents, and statistical database, among others. Major companies listed in the report are AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH.
Reasons to Buy Report
- To understand the North America hematuria treatment market landscape and identify market segments that are likely to guarantee a strong return
- To comprehend the ever-changing market landscape and stay ahead in competition
- To efficiently plan merger and acquisition, and partnership deals in the North America hematuria treatment market by identifying segments with the most promising probable sales
- To make knowledgeable business decisions from perceptive and comprehensive analysis of the market performance of various segments
- To obtain market revenue forecast of the North America hematuria treatment market based on various segments for the period 2021–2028
NORTH AMERICA HEMATURIA TREATMENT MARKET SEGMENTATION
- Drugs
- Therapies
- Others
By Indication
- Urinary Tract Infections
- Kidney Stones
- Urethritis
- Blood Cancer
- Bladder Stones
- Prostate Cancer
- Cystitis
- Trauma
- Vigorous Exercise
- Polycystic Kidney Disease
- Endometriosis
- Menstruation
By Type
- Macroscopic Hematuria
- Microscopic Hematuria
- Idiopathic Hematuria
- Jogger’s Hematuria
By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers (ASC's)
- Others
By Country
- North America
- US
- Canada
- Mexico
Companies Mentioned
- AstraZeneca
- Bristol-Myers Squibb Company
- F. HOFFMANN-LA ROCHE LTD.
- GlaxoSmithKline plc.
- Janssen Pharmaceuticals
- Merck & Co., Inc.
- Novartis AG
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Boehringer Ingelheim International GmbH
North America Hematuria Treatment Market Strategic Insights
North America Hematuria Treatment Market Report Highlights
| Report Attribute | Details |
| Market size in 2021 | US$ 351.6 Million |
| Market Size by 2028 | US$ 419.7 Million |
| CAGR (2021 - 2028) | 2.6% |
| Historical Data | 2019-2020 |
| Forecast period | 2022-2028 |
| Segments Covered |
By Treatment
|
|
Regions and Countries Covered
|
|
| North America | US, Canada, Mexico |
| Market leaders and key company profiles |
|
North America Hematuria Treatment Market Country and Regional Insights
